2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Breast Neoplasms
12
Stomach Neoplasms
10
Urinary Bladder Neoplasms
6
Carcinoma, Transitional Cell
5
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Ovarian Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
HER2-positive Gastric Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Cancer Recurrent
1
Neoplasms
1
Muscle Invasive Bladder Carcinoma
1
Muscle Invasive Bladder Cancer (MIBC)
1
Muscle Invasive Bladder Cancer
1
Metastatic HER2 Positive Gastroesophageal Junction Cancer
1
Lung Neoplasms
1
High-risk Non-muscle Invasive Bladder Cancer
1
Head and Neck Neoplasms
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
1
HER2-low Breast Cancer
1
HER2
1
Gastric Adenocarcinoma
1
Endometrial Neoplasms
1
Interventions
pembrolizumab
185
Gemcitabine
170
Paclitaxel
152
Carboplatin
137
Bevacizumab
128
Surveys and Questionnaires
118
Cisplatin
115
Docetaxel
114
Blood Specimen Collection
110
Cyclophosphamide
109
Exercise
108
Nivolumab
98
Fluorouracil
90
Capecitabine
86
Dexamethasone
81
Radiotherapy
80
Irinotecan
74
Standard of Care
69
Pemetrexed
68
Oxaliplatin
68
Leucovorin
64
Drug Therapy
64
Cetuximab
60
Erlotinib Hydrochloride
56
Sorafenib
53
atezolizumab
52
Ipilimumab
51
Doxorubicin
50
trametinib
47
Interviews as Topic
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
disitamab vedotin
×
Clear all
NCT07142200
2025-08-26
DECIDING
RenJi Hospital
Phase 2
Not yet recruiting
45 enrolled